Calidi Biotherapeutics Announces Commitment Of $25 Million In Series B Funding To Advance Stem Cell-Based Platforms For The Delivery And Potentiation Of Oncolytic Viruses To Treat Cancer
Round Type
Series B
San DiegoBiotechnologyHealth CareTherapeuticsDescription
Calidi Biotherapeutics, Inc. (“Calidi”), a clinical-stage biotechnology company that is pioneering the development of allogeneic cell-based delivery of oncolytic viruses, today announced the commitment of $25 million in Series B funding led by Jackson Investment Group (“JIG”), who has funded an initial investment of $5 million, and participation from Calidi Cure, LLC, a consortium of new and existing investors led by Allan Camaisa, CEO and Chairman of Calidi. The remaining commitment is conditioned upon the consummation of the previously announced business combination between First Light Acquisition Group (NYSEAMERICAN: FLAG) and Calidi. FLAG’s Sponsor and Metric Finance Holdings will contribute sponsor economics to the Series B investors as part of the transaction
Quick answer
Calidi Biotherapeutics raised an undisclosed amount in a Series B round, dated June 23, 2023. Calidi Biotherapeutics is based in San Diego, California, United States.
- How much did Calidi Biotherapeutics raise?
- Calidi Biotherapeutics raised an undisclosed amount in a Series B round on June 23, 2023.
- What does Calidi Biotherapeutics do?
- Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease.
- Where is Calidi Biotherapeutics based and how big is it?
- Calidi Biotherapeutics is based in San Diego, California, United States. Fundz records about 31 employees.
- Who are the decision-makers at Calidi Biotherapeutics?
- Fundz holds 1 contact at Calidi Biotherapeutics, including the CEO & Chair of the Board. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Calidi Biotherapeutics that raised within 45 days of this round, from Fundz verified event records.
- Gracell raised $150M (Post-IPO Equity) on August 7, 2023.
- Poseida Therapeutics, Inc. raised an undisclosed amount (Corporate Round) on August 7, 2023.
- Poseida Therapeutics, Inc. raised $25M on August 7, 2023.
- PredxBio raised $601K (Seed) on August 4, 2023.
- Oragenics raised $850K (Series C) on August 4, 2023.
- Ikena Oncology raised $43M on August 4, 2023.
Who to call at Calidi Biotherapeutics, and when
A new round usually means Calidi Biotherapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Calidi Biotherapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Calidi Biotherapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Calidi Biotherapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Calidi Biotherapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansCalidi Biotherapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.